Table 4. Medications administered changes over time.
| In 2009 (%) | In 2020 (%) | P value | |
| Diabetes, IGT | |||
| DPP-4 inhibitor | 0 | 37.0 | <0.01 |
| Biguanide | 19.1 | 33.3 | 0.261 |
| Thiazolidine | 40.4 | 48.1 | 0.630 |
| alpha GI | 25.5 | 7.4 | 0.067 |
| Sulfonylurea | 29.8 | 11.1 | 0.086 |
| SGLT2 inhibitor | 0 | 3.7 | 0.375 |
| Glinide | 4.3 | 0 | 0.527 |
| GLP-1 analog | 0 | 3.7 | 1.000 |
| Insulin | 27.7 | 14.8 | 0.381 |
| Dyslipidemia | |||
| Statin | 65.4 | 65.4 | 0.610 |
| Fibrate | 19.2 | 3.8 | 0.017 |
| Ezetimibe | 1.9 | 0 | 1.000 |
| EPA | 5.8 | 11.5 | 0.557 |
| Resin | 1.9 | 0 | 1.000 |
| Nicotinic acid | 1.9 | 19.2 | 0.153 |
| Probucol | 5.8 | 0 | 0.503 |
| Hypertension, among others | |||
| Ca blocker | 42.1 | 47.1 | 1.000 |
| ARB | 47.4 | 35.3 | 0.510 |
| ACE inhibitor | 5.3 | 0.0 | 1.000 |
| Alpha1 blocker | 0.0 | 0.0 | 1.000 |
| Beta blocker | 5.3 | 11.8 | 1.000 |
| Diuretics | 10.5 | 0.0 | 0.487 |
| Antiplatelet | NA | 5.0 | NA |
| Anticoagulant | NA | 12.5 | NA |
The data in this registry in 2020 was compared with the data of survey in 2009. Fisher’s exact test was used for the statistical comparison.
The percentages of medications administered to treat abnormal glucose metabolism, dyslipidemia, and hypertension are shown for the total number of patients with each disorder. DPP-4, Dipeptidyl peptidase-4; alpha GI, alpha glucosidase inhibitor; SGLT2, Sodium-glucose cotransporter-2; GLP-1, Glucagon-like peptide-1; EPA, Eicosapentaenoic acid; Ca, Calcium; ARB, Angiotensin-II receptor blocker; ACE, Angiotensin-converting enzyme inhibitor, NA; not available.